netFormulary
 Report : Medicines with links to NICE 27/11/2020 00:47:48

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Abatacept 10.01.03 Restricted Use NICE TA280: Rheumatoid arthritis - abatacept (2nd line)
Abemaciclib 08.01.05 Restricted Use NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abemaciclib 08.01.05 Restricted Use NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abiraterone Actetate 250 mg Tablets 08.03.04.02 Non Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone Actetate 250 mg Tablets 08.03.04.02 Non Formulary NICE TA259: Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy)
Adalimumab 10.01.03 Restricted Use NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab
Adalimumab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adalimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 13.05.03 Restricted Use NICE TA 146 - Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Restricted Use NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 01.05.03 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Adalimumab 01.05.03 Restricted Use NICE TA262: Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal)
Afatinib tablets 08.01.05 Non Formulary NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Aflibercept 11.08.02 Restricted Use NICE TA294: Macular degeneration (wet age-related) - aflibercept (1st line)
Aflibercept 11.08.02 Restricted Use NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Restricted Use NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Restricted Use NICE TA305: Macular oedema (central retinal vein occlusion) - aflibercept solution for injection
Aflibercept 11.08.02 Restricted Use NICE TA307: Colorectal cancer (metastatic) - aflibercept
Aflibercept 11.08.02 Restricted Use NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Alectinib 150mg hard capsules 08.01.05 Restricted Use NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab Concentrate for IV Infusion 30mg/ml 08.02.03 Restricted Use NICE TA312: Multiple sclerosis (relapsing-remitting) - alemtuzumab
Alirocumab 02.12 Restricted Use NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alteplase Injection 02.10.02 Formulary NICE TA264: Stroke (acute, ischaemic) - alteplase
Apixaban 2.5mg and 5mg Tablets 02.08.02 Restricted Use NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apixaban 2.5mg and 5mg Tablets 02.08.02 Restricted Use NICE TA245: Venous thromboembolism - apixaban (hip and knee surgery)
Apixaban 2.5mg and 5mg Tablets 02.08.02 Restricted Use NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apremilast tablets 13.05.03 Restricted Use NICE TA433: Apremilast for treating active psoriatic arthritis
Apremilast tablets 13.05.03 Restricted Use NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Restricted Use NICE TA292: Bipolar disorder (children) - aripiprazole
Arsenic Trioxide Concentrate for IV Infusion 10mg/10ml 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Atezolizumab 08.01.05 Restricted Use NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Atezolizumab 08.01.05 Restricted Use NICE TA493: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.01.05 Restricted Use NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Restricted Use NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Restricted Use NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 08.01.05 Restricted Use NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Avatrombopag 09.01.04 Restricted Use NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Axitinib 08.01.05 Non Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine Injection 100mg 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (NOT recommended)
Baricitinib tablets 10.01.03 Restricted Use NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Bee or Wasp Venom Extract Injection 03.04.02 Restricted Use NICE TA246: Venom anaphylaxis - immunotherapy pharmalgen
Belimumab Infusion 10.01.03 Non Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine Injection 25mg and 100mg Vial 08.01.01 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Bevacizumab 08.01.05 Restricted Use NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bevacizumab 08.01.05 Restricted Use NICE TA214: Breast cancer - bevacizumab (in combination with a taxane)
Bevacizumab 08.01.05 Restricted Use NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Restricted Use NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Restricted Use NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bevacizumab 08.01.05 Restricted Use NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab 08.01.05 Restricted Use NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Bivalirudin Injection 250mg 02.08.01 Restricted Use NICE TA230: Myocardial infarction (persistent ST-segment elevation) - bivalirudin
Blinatumomab 08.02.03 Restricted Use NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab 08.02.03 Restricted Use NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Boceprevir 200mg Capsules 05.03.03.02 Restricted Use NICE TA253:Hepatitis C (genotype 1) - boceprevir
Bortezomib Injection 3.5mg 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib Injection 3.5mg 08.01.05 Formulary NICE TA311: Multiple myeloma - bortezomib (induction therapy)
Bosutinib 08.01.05 Restricted Use NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Bosutinib 08.01.05 Restricted Use NICE TA229: Leukaemia (chronic myeloid) - bosutinib (NOT RECOMMENDED)
Botulinum Toxin Type A 04.09.03 Restricted Use NICE TA260: Migraine (chronic) - botulinum toxin type A
Botulinum Toxin Type A 04.09.03 Restricted Use NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Brentuximab vedotin injection 50mg 08.01.05 Restricted Use NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin injection 50mg 08.01.05 Restricted Use NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin injection 50mg 08.01.05 Restricted Use NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin injection 50mg 08.01.05 Restricted Use NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin injection 50mg 08.01.05 Restricted Use NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brigatinib 08.01.05 Restricted Use NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 210mg/1.5ml solution for injection pre-filled syringes 10.01.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel Infusion 08.01.05 Non Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib tablets 08.01.05 Non Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canakinumab 08.02.04 Non Formulary NICE TA281: Gout - canakinumab (terminated appraisal)
Canakinumab 08.02.04 Non Formulary NICE TA302: Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal)
Cannabidiol oral solution 100mg/1ml 04.08.01 Non Formulary NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol oral solution 100mg/1ml 04.08.01 Non Formulary NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Carfilzomib powder for solution for infusion 08.01.05 Formulary NICE TA457: Carfilzomib for previously treated multiple myeloma
Cemiplimab 08.01.05 Non Formulary NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Ceritinib 08.01.05 Restricted Use NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Ceritinib 08.01.05 Restricted Use NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Certolizumab Pegol Injection 200mg 10.01.03 Restricted Use NICE: TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol Injection 200mg 10.01.03 Restricted Use NICE TA186: Rheumatoid arthritis - certolizumab pegol
Certolizumab Pegol Injection 200mg 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol Injection 200mg 10.01.03 Restricted Use NICE TA415:Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol Injection 200mg 10.01.03 Restricted Use NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Cetuximab 08.01.05 Restricted Use NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Ciclosporin 0.1% eye drops 11.08.01 Restricted Use NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cilostazol 02.06.04 Non Formulary NICE TA223: Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate
Cinacalcet 09.05.01.02 Restricted Use NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Cladribine tablets 08.02 Restricted Use NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis (replaces TA493)
Clopidogrel Tablets 75mg and 300mg 02.09 Formulary NICE TA210: Vascular disease - clopidogrel and dipyridamole
Colistimethate Sodium 1,662,500 unit inhalation powder capules 05.01.07 Restricted Use NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase Clostridium histolyticum 900microgram Injection 10.03.01 Non Formulary NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Restricted Use NICE TA296: Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib
Crizotinib 08.01.05 Restricted Use NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Restricted Use NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Restricted Use NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Dabigatran capsules 02.08.02 Restricted Use NICE TA249: Atrial fibrillation - dabigatran etexilate
Dabigatran capsules 02.08.02 Restricted Use NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib capsules 08.01.05 Non Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib capsules 08.01.05 Non Formulary NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Daclatasvir 30mg & 60mg tablets 05.03.03.02 Restricted Use NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.02 Non Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dacomitinib 08.01.05 Restricted Use NICE TA595:; Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Type 2 diabetes - Dapagliflozin combination therapy
Daratumumab 08.02.03 Restricted Use NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.02.03 Restricted Use NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Daunorubicin and cytarabine liposomal injection 08.01.02 Restricted Use NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 60mg in 1ml 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Denosumab injection 120mg/1.7ml 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours
Dexamethasone 700 microgram intravitreal implant 11.04.01 Restricted Use NICE TA229: Macular oedema (retinal vein occlusion) - dexamethasone
Dexamethasone 700 microgram intravitreal implant 11.04.01 Restricted Use NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dimethyl fumarate 120mg and 240mg E/C capsules 08.02.04 Restricted Use NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl fumarate 30mg and 120mg tablets 13.05.02 Restricted Use NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dipyridamole MR Capsule 200mg 02.09 Formulary NICE TA210: Vascular disease - clopidogrel and dipyridamole
Donepezil Hydrochloride Tablets 5mg and 10mg 04.11 Formulary NICE TA217: Alzheimers disease - donepezil, galantamine, rivastigmine and memantine
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dupilumab 10.01.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01.05 Restricted Use NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Edoxaban 15mg & 30mg tablets 02.08.02 Formulary NICE TA354:Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban 15mg & 30mg tablets 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation
Elbasvir 50mg with grazoprevir 100mg tablets 05.03.03.02 Restricted Use NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 25mg tablets 09.01.04 Restricted Use NICE TA382: Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)
Eltrombopag 25mg tablets 09.01.04 Restricted Use NICE TA293: Thrombocytopenic purpura - eltrombopag
Eluxadoline 01.02 Restricted Use NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entrectinib 100mg capsules 08.01.05 Restricted Use NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Enzalutamide capsules 40mg 08.03.04.02 Restricted Use NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Enzalutamide capsules 40mg 08.03.04.02 Restricted Use NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eribulin Injection 08.01.05 Restricted Use NICE TA250: Breast cancer (advanced) - eribulin
Eribulin Injection 08.01.05 Restricted Use NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Eribulin Injection 08.01.05 Restricted Use NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Erlotinib 08.01.05 Restricted Use NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Erlotinib 08.01.05 Restricted Use NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib
Erlotinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Restricted Use NICE TA162: Lung cancer (non-small-cell) - erlotinib
Ertugliflozin tablets 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin tablets 06.01.02.03 Formulary NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Etanercept 10.01.03 Formulary NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etelcalcetide 09.05.01.02 Restricted Use NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus Tablets 08.01.05 Restricted Use NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus Tablets 08.01.05 Restricted Use NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus Tablets 08.01.05 Restricted Use NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus Tablets 08.01.05 Restricted Use NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Everolimus Tablets 08.01.05 Restricted Use NICE TA295: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (Not recommended)
Evolocumab 02.12 Restricted Use NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide 2mg MR Injection 06.01.02.03 Restricted Use NICE TA248: Diabetes (type 2) - exenatide (prolonged release)
Ezetimibe Tablets 10mg 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Fingolimod 500mcg Capsules 08.02.04 Restricted Use NICE TA254: Multiple sclerosis (relapsing-remitting) - fingolimod
Fluocinolone intravitreal implant 11.04.01 Restricted Use NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone intravitreal implant 11.04.01 Restricted Use NICE TA301: Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271)
Fremanezumab 04.06 Restricted Use TA631
Fulvestrant 08.03.04.01 Restricted Use NICE TA239: Breast cancer (metastatic) - fulvestrant
Fulvestrant 08.03.04.01 Restricted Use NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Galantamine 04.11 Formulary NICE TA217: Alzheimers disease - donepezil, galantamine, rivastigmine and memantine
Galantamine MR Capsules 04.11 Formulary NICE TA217: Alzheimers disease - donepezil, galantamine, rivastigmine and memantine
Gefitinib Tablets 250mg 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine Injection 200mg and 1g 08.01.03 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemtuzumab ozogamicin 5mg powder for concentrate for solution for infusion 08.02.03 Restricted Use NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Gilteritinib 40mg tablets 08.01.05 Restricted Use NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32)
Glecaprevir with pibrentasvir 100mg/40mg tablets 05.03.03.02 Non Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
Golimumab Injection 50mg 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab Injection 50mg 10.01.03 Restricted Use NICE TA220: Psoriatic arthritis - golimumab
Golimumab Injection 50mg 10.01.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Golimumab Injection 50mg 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab Injection 50mg 10.01.03 Restricted Use NICE TA225: Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab
Guselkumab solution for injection 100mg 10.01.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Ibrutinib capsules 140mg 08.01.05 Restricted Use NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib capsules 140mg 08.01.05 Restricted Use NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib capsules 140mg 08.01.05 Restricted Use NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Idelalisib tablets 100mg & 150mg 08.01.05 Restricted Use NICE TA328: Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)
Idelalisib tablets 100mg & 150mg 08.01.05 Restricted Use NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Imatinib Tablets 100mg and 400mg 08.01.05 Formulary NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Imatinib Tablets 100mg and 400mg 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib Tablets 100mg and 400mg 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196)
Imatinib Tablets 100mg and 400mg 08.01.05 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute exacerbations) - infliximab
Infliximab 01.05.03 Restricted Use NICE TA140: Ulcerative colitis (subacute manifestations) - infliximab
Infliximab 13.05.03 Restricted Use NICE TA134- Infliximab for the treatment of adults with psoriasis
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA134: Psoriasis - infliximab
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 10.01.03 Formulary NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab
Inositol Nicotinate 02.06.04 Non Formulary NICE TA223: Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate
Inotuzumab ozogamicin 1 mg powder for concentrate for solution for infusion 08.02.03 Restricted Use NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Beta 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32)
Interferon Beta 08.02.04 Restricted Use NICE TA32: Multiple sclerosis - beta interferon and glatiramer acetate
Interferon Beta 08.02.04 Restricted Use NICE TA32: Multiple sclerosis - beta interferon and glatiramer acetate
Interferon Beta 08.02.04 Non Formulary NICE TA32: Multiple sclerosis - beta interferon and glatiramer acetate
Interferon beta 08.02.04 Non Formulary NICE TA32: Multiple sclerosis - beta interferon and glatiramer acetate
Ipilimumab Concentrate for Intravenous Infusion, 08.01.05 Non Formulary NICE TA268: Melanoma (stage III or IV) - ipilimumab
Ipilimumab Concentrate for Intravenous Infusion, 08.01.05 Non Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Irinotecan hydrochloride trihydrate (as irinotecan sucrosofate salt in a pegylated liposomal formulation) 08.01.05 Non Formulary NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Ivabradine Tablets 5mg and 7.5mg 02.06.03 Formulary NICE TA267: Chronic heart failure - ivabradine
Ixazomib 08.01.05 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab injection 80mg 13.05.03 Restricted Use NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab injection 80mg 13.05.03 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lanadelumab injection 300mg/2ml 03.04.03 Restricted Use NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Non Formulary NICE TA257: Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)
Ledipasvir/sofosbuvir 90/400mg tablets 05.03.03.02 Restricted Use NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA171: Multiple myeloma - lenalidomide
Lenalidomide 08.02.04 Formulary NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Formulary NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenvatinib 08.01.05 Non Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Letermovir 05.03.02.02 Non Formulary NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Lubiprostone 01.06.07 Restricted Use NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lusutrombopag 09.01.04 Restricted Use NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Mannitol inhalation powder 03.07 Restricted Use NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Memantine Hydrochloride 04.11 Formulary NICE TA217: Alzheimers disease - donepezil, galantamine, rivastigmine and memantine
Mepolizumab injection 100mg 03.04.02 Restricted Use NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Methylnaltrexone 01.06.06 Non Formulary NICE TA277: Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)
Midostaurin capsules 25mg 08.01.05 Non Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide Infusion 4mg 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide
Mirabegron tablets MR 07.04.02 Restricted Use NICE TA290: Overactive bladder - mirabegron
Naftidrofuryl Oxalate Capsule 100mg 02.06.04 Formulary NICE TA223: Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate
Nalmefene 04.10.01 Non Formulary NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Restricted Use NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone with bupropion 04.10 Non Formulary NICE TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Non Formulary NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
Neratinib 08.01.05 Formulary NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Nilotinib Capsules 200mg 08.01.05 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Nilotinib Capsules 200mg 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib Capsules 200mg 08.01.05 Formulary NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Nintedanib 08.01.05 Restricted Use NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nintedanib 08.01.05 Restricted Use NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nivolumab 08.01.05 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.01.05 Restricted Use NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.01.05 Restricted Use NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.01.05 Restricted Use NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.01.05 Restricted Use NICE TA482: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.01.05 Restricted Use NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.01.05 Restricted Use NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
Nusinersen 04.12 Non Formulary NICE TA588: Nusinersen for treating spinal muscular atrophy
Obeticolic acid 01.09.01 Restricted Use TA443:Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Restricted Use NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab 08.02.03 Restricted Use NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Ocrelizumab concentrate for solution for infusion 300mg 08.02.03 Restricted Use NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab concentrate for solution for infusion 300mg 08.02.03 Restricted Use NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin intravitreal injection 11.08.02 Restricted Use NICE TA297: Vitreomacular traction - ocriplasmin
Ofatumumab 08.02.03 Restricted Use NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Olaparib 50mg capsules 08.02.04 Restricted Use NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaparib 50mg capsules 08.02.04 Restricted Use NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaparib 50mg capsules 08.02.04 Restricted Use NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Omalizumab 03.04.02 Restricted Use NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab
Omalizumab 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/paritaprevir/ritonavir 12.5/75/50mg tablets 05.03.03.02 Restricted Use NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Paclitaxel 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Non Formulary NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
Palbociclib 08.01.05 Restricted Use NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Palbociclib 08.01.05 Restricted Use NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Panitumumab infusion 100mg/5ml and 400mg/20ml 08.01.05 Restricted Use NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat capsules 08.01.05 Restricted Use NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patiromer sorbitex calcium powder 09.02.01.01 Formulary NICE TA623: Patiromer for treating hyperkalaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon beta-1a 08.02.04 Restricted Use NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pegloticase 10.01.04 Non Formulary NICE TA291: Gout (tophaceous, severe debilitating, chronic) - pegloticase
Pembrolizumab infusion 08.01.05 Restricted Use NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab infusion 08.01.05 Restricted Use NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab infusion 08.01.05 Restricted Use NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab infusion 08.01.05 Restricted Use NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab infusion 08.01.05 Restricted Use NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab infusion 08.01.05 Restricted Use NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab infusion 08.01.05 Restricted Use NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab infusion 08.01.05 Restricted Use NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pemetrexed Injection 100mg and 500mg 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed Injection 100mg and 500mg 08.01.03 Formulary NICE TA309: Lung cancer (non small cell, non squamous) - pemetrexed
Pentosan polysulfate sodium capsules 100mg 07.04.03 Formulary NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome
Pentoxifylline 02.06.04 Restricted Use NICE TA223: Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate
Pertuzumab 420mg/14ml concentrate for solution for infusion 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 420mg/14ml concentrate for solution for infusion 08.01.05 Restricted Use NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 420mg/14ml concentrate for solution for infusion 08.01.05 Restricted Use NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pirfenidone 267mg capsule 03.11 Restricted Use NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone injection 29mg 08.01.02 Restricted Use NICE TA306: Lymphoma (non Hodgkins, relapsed, refractory) - pixantrone monotherapy
Polatuzumab vedotin 140mg concentrate for solution for infusion 08.01.05 Restricted Use NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
Pomalidomide 08.02.04 Restricted Use NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Restricted Use NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel Tablets 5mg and 10mg 02.09 Formulary NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Prucalopride Tablets 1mg and 2mg 01.06.07 Restricted Use NICE TA211: Constipation (women) - prucalopride
Raloxifene Hydrochloride tablets 60mg 06.04.01.01 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ranibizumab 11.08.02 Restricted Use NICE TA274: Macular oedema (diabetic)
Ranibizumab 11.08.02 Restricted Use NICE TA283: Macular oedema (retinal vein occlusion)
Ranibizumab 11.08.02 Restricted Use NICE TA298: Choroidal neovascularisation (pathological myopia)
Regorafenib 08.01.05 Non Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Retigabine 04.08.01 Formulary NICE TA232: Epilepsy (partial) - retigabine (adjuvant)
Ribavirin 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.01.05 Restricted Use NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Ribociclib 08.01.05 Restricted Use NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Rifaximin tablets 550mg 05.01.07 Restricted Use NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Risankizumab 10.01.03 Restricted Use NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
Rituximab 10.01.03 Restricted Use NICE TA308: Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids)
Rituximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab Concentrate for IV Infusion 100mg/10ml and 500mg/50ml 08.02.03 Formulary NICE TA226: Lymphoma (follicular non-Hodgkins) - rituximab
Rituximab Concentrate for IV Infusion 100mg/10ml and 500mg/50ml 08.02.03 Formulary NICE TA243: Follicular lymphoma - rituximab (review)
Rivaroxaban tablets 02.08.02 Restricted Use NICE TA261: Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban
Rivaroxaban tablets 02.08.02 Restricted Use NICE TA287:Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban
Rivaroxaban tablets 02.08.02 Restricted Use NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban tablets 02.08.02 Restricted Use NICE TA256: Atrial fibrillation (stroke prevention) - rivaroxaban
Rivaroxaban tablets 02.08.02 Restricted Use NICE TA 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivastigmine 04.11 Formulary NICE TA217: Alzheimers disease - donepezil, galantamine, rivastigmine and memantine
Roflumilast 03.03.03 Restricted Use NICE TA244: Superceded by TA461
Roflumilast 03.03.03 Restricted Use NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim Injection 250mcg 09.01.04 Restricted Use NICE TA221: Thrombocytopenic purpura - romiplostim
Rucaparib tablets 08.02.04 Restricted Use NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Ruxolitinib 08.01.05 Restricted Use NICE TA356: Ruxolitinib for treating polycythaemia vera (terminated appraisal)
Ruxolitinib 08.01.05 Restricted Use NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril and valsartan tablets 02.05.05.02 Restricted Use NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 13.05.03 Restricted Use NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Restricted Use NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 13.05.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Simeprevir 400mg tablets 05.03.03.02 Restricted Use NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sodium zirconium cyclosilicate powder 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 150mg capsules 05.03.03.02 Restricted Use NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir 400mg/velpatasvir 100mg tablets 05.03.03.02 Restricted Use NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir with velpatasvir and voxilaprevir 05.03.03.02 Non Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Sunitinib 08.01.05 Non Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus Ointment 0.03% 13.05.03 Restricted Use NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Tacrolimus Ointment 0.1% 13.05.03 Restricted Use NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Telaprevir 375mg Tablets 05.03.03.02 Restricted Use NICE TA252: Hepatitis C (genotype 1) - telaprevir
Tenofovir Disproxil tablets 245mg 05.03.01 Restricted Use NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B
Teriflunomide tablets 14mg 08.02.04 Restricted Use NICE TA303: Multiple sclerosis (relapsing) - teriflunomide
Thalidomide 50mg Capsules 08.02.04 Formulary NICE TA228: Multiple myeloma (first line) - bortezomib and thalidomide
Ticagrelor 90mg Tablets 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Ticagrelor 90mg Tablets 02.09 Restricted Use NICE TA236: Acute coronary syndromes - ticagrelor
Tildrakizumab 13.05.03 Restricted Use NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tobramycin 05.01.04 Restricted Use NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tobramycin 05.01.04 Restricted Use NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab 10.01.03 Formulary NICE TA247: Rheumatoid arthritis - tocilizumab
Tocilizumab 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib tablets 5mg 10.01.03 Restricted Use NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib tablets 5mg 10.01.03 Restricted Use NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib tablets 5mg 10.01.03 Restricted Use NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan 15mg, 30mg & 60mg tablets 06.05.02 Non Formulary NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Non Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Non Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab emtansine infusion 100mg & 160mg 08.01.05 Restricted Use NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trastuzumab emtansine infusion 100mg & 160mg 08.01.05 Restricted Use NICE TA371: Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
Trastuzumab IV Infusion 150mg 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab IV Infusion 150mg 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab IV Infusion 150mg 08.01.05 Formulary NICE TA257: Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)
Trastuzumab IV Infusion 150mg 08.01.05 Formulary NICE TA107: Breast cancer (early) - trastuzumab
Trifluridine with tipiracil tablets 08.01.05 Restricted Use NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 13.05.03 Restricted Use NICE TA313: Superceded by TA340
Ustekinumab 13.05.03 Restricted Use NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 13.05.03 Restricted Use NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Restricted Use NICE TA340: Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313)
Ustekinumab 13.05.03 Restricted Use NICE TA633L Ustekinumab for treating moderately to severely active ulcerative colitis
Varenicline 04.10 Formulary NICE TA123 Smoking cessation - varenicline
Vedolizumab 300mg concentrate for infusion 01.05.03 Restricted Use NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vedolizumab 300mg concentrate for infusion 01.05.03 Restricted Use NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vemurafenib 08.01.05 Non Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Venetoclax 08.01.05 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 08.01.05 Non Formulary NICE TA489: Vismodegib for treating basal cell carcinoma
Vortioxetine tablets 04.03.04 Non Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Zopiclone Tablets 3.75mg and 7.5mg 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Kettering General Hospital